卫生保健专业人员主动脉瓣狭窄资源
只要我们齐心协力,我们就能有所作为.
The 目标:主动脉瓣狭窄 quality improvement program exists to enhance the patient experience from symptom onset to appropriate diagnosis and follow-through, 及时治疗和疾病管理. 参见下面的指南、临床和患者教育资源.
指导资源:
心脏瓣膜病指南 (网站)
Key Implications for Clinicians in the 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease
在您对疑似瓣膜性心脏病患者的评估中, learn the diagnostic strategies for early detection of valvular disease and appropriate long-term management. Discover appropriate tools for assessment and intervention based on valvular disease stage, 特别是在二尖瓣反流和主动脉狭窄的情况下.
网络研讨会中提到的资源
- Top Things to Know: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
- 执行概要
- Perspective to 2020 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease
- 美国心脏协会临床更新 瓣膜性心脏病(PPTX -可定制) | (pdf版)
- 演讲 幻灯片设置 (pdf)
- VHD口袋指南 (购买)
- 啊哈线上电子游戏飞禽走兽: New guidelines call for less use of surgery to treat heart valve disease
- 线上电子游戏飞禽走兽发布: Updated guideline for heart valve disease spotlights less invasive 治疗s
- 线上电子游戏飞禽走兽发布: Quality of care initiative seeks to improve outcomes for heart valve patients
临床资料:
Thanks to the facilities participating in the 目标:主动脉瓣狭窄 program, several key areas have been identified along the patient journey where barriers to care exist. 这些关键领域包括:
- Identification of patients diagnosed with moderate or severe aortic stenosis
- Once identified, urgently moving the patient through the journey to appropriate definitive 治疗
- 多学科和共同决策过程的变化
To learn more regarding the 目标:主动脉瓣狭窄 program and the suggested best practices and solutions from experts in the field addressing these barrier to care, 请参阅下面的参考资料.
播客:
主动脉狭窄治疗不足,一种致命的心脏瓣膜疾病
主动脉狭窄治疗不足,一种致命的心脏瓣膜疾病
本集讨论了主动脉瓣狭窄的治疗不足, one of the most common and serious – but undertreated – heart valve diseases. 听听两位专家对这个问题的看法. 布莱恩·林德曼,M.D., 摩根士丹利资本国际(MSCI), medical director of the Structural Heart and Valve Center at Vanderbilt University Medical Center, 博士和. Sammy Elmariah, M.D.他是介入心脏病学和加州大学旧金山分校健康中心的主任. Tune in to learn about the consequences of undertreating aortic stenosis, 可能的解决方案, 和更多的. 主动脉狭窄治疗不足,一种致命的心脏瓣膜疾病
主动脉瓣狭窄是一种致命的心脏瓣膜疾病,治疗不足
病人资源:
- 主动脉瓣狭窄情况说明 (pdf)
- 什么是主动脉瓣狭窄? (pdf)
- 主动脉狭窄症状追踪器 (pdf)
- 主动脉瓣狭窄讨论指南:充分利用你的预约 (pdf)
- 为什么我需要心脏瓣膜手术? (pdf) 西班牙语 (pdf)
- 什么是TAVI/TAVR? (pdf)
- 主动脉瓣狭窄和COVID常见问题解答 (pdf)
媒体报道:
- Optimizing Experience, Outcomes and Equity for 主动脉瓣狭窄 Patients | Modern Healthcare
- 解决严重心脏瓣膜疾病治疗不足的问题
- 美国心脏协会说主动脉瓣狭窄没有得到充分的治疗和诊断
加入我们的电邮名单
请 加入我们的电邮名单 通知未来的活动和项目机会.